31. S69 Verification of genetic associations with scleroderma associated interstitial lung disease. (12th November 2019) Authors: Stock, CJW; DeLauretis, A; Visca, D; Daccord, C; Kokosi, M; Kouranos, V; Margaritopoulos, G; George, PM; Molyneaux, PL; Chua, F; Maher, TM; Abraham, DJ; Denton, CP; Ong, V; Wells, AU; Renzoni, EA Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
32. S77 The idiopathic pulmonary fibrosis patients reported outcome measure (IPF-PROM) is reliable and valid for use in populations with IPF. (December 2018) Authors: Russell, AM; Wickremasinghe, M; Renzoni, E; Adamali, H; Borril, Z; Fletcher, S; Maher, TM; Ng Man Kwong, G; Saketkoo, LA; Fleming, S; Cullinan, P Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
33. S86 Serum biomarkers in SSc-ILD: association with presence, severity and prognosis. (12th November 2019) Authors: Stock, CJW; Visca, D; DeLauretis, A; Daccord, C; Kokosi, M; Alfieri, V; Kouranos, V; Margaritopoulos, G; George, PM; Molyneaux, PL; Chua, F; Maher, TM; Ong, V; Abraham, DJ; Denton, CP; Wells, AU; Renzoni, EA Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
34. S98 Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis (IPF) under pirfenidone treatment. (15th November 2016) Authors: Kreuter, M; Spagnolo, P; Wuyts, W; Renzoni, E; Koschel, D; Bonella, F; Maher, TM; Kolb, M; Weycker, D; Kirchgässler, K; Costabel, U Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
35. S98 Early Clinical Experience with Pirfenidone For Idiopathic Pulmonary Fibrosis (IPF) in the UK: Interim Results from a UK Cohort. (19th November 2012) Authors: Parfrey, H; Leonard, C; Gibbons, MA; Harris, E; Frank, R; Sharp, C; Dew, RM; Maher, TM Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
36. T1 Meta-analysis of idiopathic pulmonary fibrosis genome-wide analyses identifies three novel genetic signals associated with disease susceptibility. (12th November 2019) Authors: Allen, RJ; Guillen-Guio, B; Oldham, JM; Ma, SF; Dressen, A; Paynton, ML; Kraven, LM; Obeidat, M; Li, X; Braybrooke, R; Fingerlin, TE; Hall, IP; Sayers, I; Tobin, MD; Maher, TM; Schwartz, DA; Yaspan, BL; Molyneaux, PL; Flores, C; Noth, I Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
37. T3 Itaconate drives the resolution of pulmonary fibrosis. (12th November 2019) Authors: Ogger, PP; Ghai, P; Hewitt, RJ; Molyneaux, PL; Maher, TM; Lloyd, CM; Byrne, AJ Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗